Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (2405)	2/18/1998 11:01:00 PM
From: Bradpalm1	Read Replies (1) \| Respond to of 7041

<< A 50% drop out rate is not good, but many initial trials do have high drop out rates.>> Brad, we're talking about Phase III trials here --- NOT initial Phase I or II trials. "not good" is a profound understatement for a drug presumably vying for 'fast-track' NDA status if submitted within the next two weeks (approval of Pfizer's Viagra by the FDA is apparently imminent). Sounds like apomorphine has a better chance of a NDA submission and FDA approval than Vasomax. Bradpalm1

To: Brander who wrote (2405)	2/19/1998 3:05:00 AM
From: Bill Wexler	Respond to of 7041

<<Zonagen bounced off 20 today, and 20 is the number the most vocal short said it would never reach again.>> I said it was unlikely to do so. I was speculating on the short term price trend - which is always dangerous to do; nonetheless, I came pretty close (within 12%) of prediciting a short-term top...not great, but not bad. More importantly, I remain 100% correct about the fundamentals of the company, and as long as the fundamentals (including the prospects of its ineffective ED drug - Vasomax) remain the same or worsen, I will eventually be proven correct and the price will fall to the floor. I used the recent runup as an opportunity to short more.